605177.SS(605177.SS)
605177.SS
Zhejiang East Asia Pharmaceutical Co., Ltd. specializes in the development and manufacturing of generic pharmaceuticals, primarily in China. The company has a competitive edge through its established distribution networks and a diverse product portfolio that includes over 200 generic drugs across various therapeutic areas.
The company generates revenue primarily through the sale of generic drugs, leveraging its extensive distribution network in China. Its competitive advantages include a broad product portfolio, established relationships with healthcare providers, and a focus on cost-effective production processes.
Changes in regulatory approval timelines for new generic drugs
Fluctuations in raw material costs, particularly APIs
Market share changes in the Chinese pharmaceutical market
Partnerships or collaborations with larger pharmaceutical firms
Regulatory changes impacting drug approval processes
Technological disruptions in drug manufacturing
Increased competition from domestic and international generic manufacturers
Potential for price wars in the generic drug market
Negative operating cash flow impacting liquidity
High valuation multiples (EV/EBITDA at 77.2x) may indicate overvaluation risk
moderate - The pharmaceutical sector is somewhat insulated from economic downturns, but demand for non-essential medications can decline during recessions.
Interest rates affect the company mainly through financing costs for expansion and R&D, impacting overall profitability and valuation multiples.
minimal - The company has a moderate debt-to-equity ratio, indicating limited reliance on credit markets.
value - Investors may be attracted due to the low price-to-book ratio (0.9x) indicating potential undervaluation.
high - The stock has shown significant volatility with a 1-year return of -25.7%.